Jeffrey Tice, MD
Associate Professor, Department of Medicine (General Internal Medicine), UCSF
Cancer Center Program Memberships
Breast OncologyEducation
Dartmouth College, Hanover, NH, BA, 06/1983, Math; Philosophy
San Francisco State University, 05/1989, Pre-medical classed
University of California, San Francisco, MD, 06/1994, Medicine
University of California, San Francisco, 06/1997, Internal Medicine
University of California, San Francisco, Postdoctoral, 06/1999, Research/Epidmiology
Professional Experience
-
1984-1986
Peace Corps Volunteer, Bangassou, Central African Republic -
1987 - 1992
Programmer/Analyst III, Department of Epidemiology, University of California, San Francisco -
1999-2004
Assistant Adjunct Professor of Medicine, Division of General Internal Medicine, Department of Medicine, University of California, San Francisco -
2005-2011
Assistant Professor of Medicine, Division of General Internal Medicine, Department of Medicine, University of California, San Francisco -
2012-present
Associate Professor of Medicine, Division of General Internal Medicine, Department of Medicine, University of California, San Francisco
Honors & Awards
- 2013
UCSF Research Mentoring Award - 2009
Society of General Internal Medicine- CA Region- Outstanding Clinician Investigator Award - 2003
Robert Crede Award for Clinical Research, UCSF Division of General Internal Medicine - 2002-2004
Building Interdisciplinary Research Careers in Women's Health (BIRCWH) Faculty Scholar - 1994
Alpha Omega Alpha, UCSF - 1990-1994
Regents Scholarship, UCSF - 1983
Summa Cum Laude, Dartmouth College - 1982
Phi Beta Kappa, Dartmouth College - 1979-1983
Rufous Choate Scholar, Dartmouth College - 1979-1983
IBM Thomas J. Watson Scholar
Selected Publications
- Braithwaite D, Miglioretti DL, Zhu W, Demb J, Trentham-Dietz A, Sprague B, Tice JA, Onega T, Henderson LM, Buist DSM, Ziv E, Walter LC, Kerlikowske K. Family History and Breast Cancer Risk Among Older Women in the Breast Cancer Surveillance Consortium Cohort. JAMA Intern Med. 2018 Apr 01; 178(4):494-501.
View on PubMed - Kazi DS, Penko J, Coxson PG, Moran AE, Ollendorf DA, Tice JA, Bibbins-Domingo K. Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial. JAMA. 2017 08 22; 318(8):748-750.
View on PubMed - Shieh Y, Hu D, Ma L, Huntsman S, Gard CC, Leung JWT, Tice JA, Ziv E, Kerlikowske K, Cummings SR. Joint relative risks for estrogen receptor-positive breast cancer from a clinical model, polygenic risk score, and sex hormones. Breast Cancer Res Treat. 2017 Nov; 166(2):603-612.
View on PubMed - Tice JA, Kerlikowske K. Supplemental Breast Cancer Screening: A Density Conundrum. J Gen Intern Med. 2017 Jun; 32(6):593-594.
View on PubMed - Shieh Y, Eklund M, Madlensky L, Sawyer SD, Thompson CK, Stover Fiscalini A, Ziv E, Van't Veer LJ, Esserman LJ, Tice JA. Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial. J Natl Cancer Inst. 2017 01; 109(5).
View on PubMed - Ziv E, Tice JA, Sprague B, Vachon CM, Cummings SR, Kerlikowske K. Using Breast Cancer Risk Associated Polymorphisms to Identify Women for Breast Cancer Chemoprevention. PLoS One. 2017; 12(1):e0168601.
View on PubMed - Kerlikowske K, Gard CC, Tice JA, Ziv E, Cummings SR, Miglioretti DL. Risk Factors That Increase Risk of Estrogen Receptor-Positive and -Negative Breast Cancer. J Natl Cancer Inst. 2017 05; 109(5).
View on PubMed - Whittington MD, McQueen RB, Ollendorf DA, Tice JA, Chapman RH, Pearson SD, Campbell JD. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis. Ann Allergy Asthma Immunol. 2017 Feb; 118(2):220-225.
View on PubMed - Shieh Y, Hu D, Ma L, Huntsman S, Gard CC, Leung JW, Tice JA, Vachon CM, Cummings SR, Kerlikowske K, Ziv E. Breast cancer risk prediction using a clinical risk model and polygenic risk score. Breast Cancer Res Treat. 2016 Oct; 159(3):513-25.
View on PubMed - Kazi DS, Moran AE, Coxson PG, Penko J, Ollendorf DA, Pearson SD, Tice JA, Guzman D, Bibbins-Domingo K. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease. JAMA. 2016 Aug 16; 316(7):743-53.
View on PubMed - Reed SJ, Shore KK, Tice JA. Effectiveness and Value of Integrating Behavioral Health Into Primary Care. JAMA Intern Med. 2016 05 01; 176(5):691-2.
View on PubMed - Dallal CM, Lacey JV, Pfeiffer RM, Bauer DC, Falk RT, Buist DS, Cauley JA, Hue TF, LaCroix AZ, Tice JA, Veenstra TD, Xu X, Brinton LA. Estrogen Metabolism and Risk of Postmenopausal Endometrial and Ovarian Cancer: the B ~ FIT Cohort. Horm Cancer. 2016 Feb; 7(1):49-64.
View on PubMed - Chahal HS, Marseille EA, Tice JA, Pearson SD, Ollendorf DA, Fox RK, Kahn JG. Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population. JAMA Intern Med. 2016 Jan; 176(1):65-73.
View on PubMed - Tice JA, Kazi DS, Pearson SD. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels: Effectiveness and Value. JAMA Intern Med. 2016 Jan; 176(1):107-8.
View on PubMed - Livaudais-Toman J, Karliner LS, Tice JA, Kerlikowske K, Gregorich S, Pérez-Stable EJ, Pasick RJ, Chen A, Quinn J, Kaplan CP. Impact of a primary care based intervention on breast cancer knowledge, risk perception and concern: A randomized, controlled trial. Breast. 2015 Dec; 24(6):758-66.
View on PubMed - Tice JA, Chahal HS, Ollendorf DA. Comparative Clinical Effectiveness and Value of Novel Interferon-Free Combination Therapy for Hepatitis C Genotype 1: Summary of California Technology Assessment Forum Report. JAMA Intern Med. 2015 Sep; 175(9):1559-60.
View on PubMed - Hart V, Reeves KW, Sturgeon SR, Reich NG, Sievert LL, Kerlikowske K, Ma L, Shepherd J, Tice JA, Mahmoudzadeh AP, Malkov S, Sprague BL. The effect of change in body mass index on volumetric measures of mammographic density. Cancer Epidemiol Biomarkers Prev. 2015 Nov; 24(11):1724-30.
View on PubMed - Tice JA, Miglioretti DL, Li CS, Vachon CM, Gard CC, Kerlikowske K. Breast Density and Benign Breast Disease: Risk Assessment to Identify Women at High Risk of Breast Cancer. J Clin Oncol. 2015 Oct 01; 33(28):3137-43.
View on PubMed - Falk RT, Dallal CM, Lacey JV, Bauer DC, Buist DS, Cauley JA, Hue TF, LaCroix AZ, Tice JA, Pfeiffer RM, Xu X, Veenstra TD, Brinton LA. Estrogen Metabolites Are Not Associated with Colorectal Cancer Risk in Postmenopausal Women. Cancer Epidemiol Biomarkers Prev. 2015 Sep; 24(9):1419-22.
View on PubMed - Kerlikowske K, Zhu W, Tosteson AN, Sprague BL, Tice JA, Lehman CD, Miglioretti DL. Identifying women with dense breasts at high risk for interval cancer: a cohort study. Ann Intern Med. 2015 May 19; 162(10):673-81.
View on PubMed